MedTrace Logo

Clinical Study to Evaluate the Possible Efficacy and Safety of L- Carnitine and Sildenafil in Children Having Beta Thalassemia With Increased Tricuspid Regurgitant Jet Velocity

NCT05584956 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2022-10-18

No results posted yet for this study

Summary

This study aims to investigate the possible efficacy and safety of L\_Carnitine and Sildenafil on patient with Beta thalassemia complicated with increased Tricuspid Regurgitant Jet Velocity

Conditions

  • Beta Thalassemia With Increased Tricuspid Regurgitant Jet Velocity

Interventions

DRUG

L_carnitine

l-carnitine stabilizes red blood cell membranes and thus improves the anemic state\[

DRUG

Sildenafil

selective and potent inhibitor of cGMP-specific phosphodiesterase 5 (PDE5), which promotes smooth muscle relaxation in lung vasculature, has been used successfully in the treatment of primary and secondary PH.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Sahar Kamal Hegazy, Professor · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-08
Primary Completion
2023-07-08
Completion
2024-07-08

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05584956 on ClinicalTrials.gov